Abstract
Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilotinib-resistant cell line, K562NR, and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel therapy for CML.
Highlights
Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML
Nilotinib has shown superiority over imatinib in first-line treatment for CML-chronic phase (CP) patients, the management of CML following the development of nilotinib resistance remains a challenge
Dasatinib is an effective therapy after imatinib and nilotinib therapy failure in CML patients [6]
Summary
Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. To the editor The BCR/ABL kinase inhibitor, imatinib, is the single effective and the standard treatment for chronic myeloid leukemia (CML) [1]. In Evaluating Nilotinib Efficacy and Safety in clinical Trials-newly diagnosed CML (ENESTnd), nilotinib has shown superior efficacy as front line treatment for patients with CML-chronic phase (CP) in comparison with imatinib [4,5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
